Examkin

All practice questions

4736 questions

All types4,736Multiple choice2,413Multiple select567Numeric127Matching858Ordering771
Question 3181Question →

An ambulatory infectious disease clinic evaluates a 45-year-old male patient who recently received a diagnosis of active cavitary pulmonary tuberculosis. His initial sputum acid-fast bacilli (AFB) smear is positive, and rapid molecular testing has confirmed the presence of a pan-susceptible Mycobacterium tuberculosis isolate. As he prepares to commence standard antituberculous pharmacotherapy, the clinical team formulates his longitudinal care plan.

Arrange the following steps representing the appropriate monitoring and treatment evaluation protocol for this patient in the correct chronological sequence.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is to first perform baseline testing, then transition to a two-drug phase at exactly 8 weeks, subsequently review the finalized 8-week culture, extend the continuation phase based on that delayed result, and finally verify treatment completion at 9 months.
The chronological sequence for monitoring and treating cavitary pulmonary tuberculosis follows a strict protocol. Baseline safety labs and visual acuity testing must be obtained before initiating therapy. At exactly 8 weeks, the intensive phase concludes, and therapy is de-escalated to a two-drug continuation phase (assuming pan-susceptibility). Because mycobacterial cultures take several weeks to grow, the finalized results of the 8-week sputum culture are reviewed after the patient has already entered the continuation phase. Upon discovering that this 8-week culture remains positive in a patient with cavitary disease, treatment evaluation protocols require extending the continuation phase from 4 months to 7 months. Finally, clinical resolution is verified at the end of the newly adjusted 9-month course.

Step-by-Step Solution

1
Perform baseline visual acuity testing and a hepatic function panel before initiating the four-drug intensive regimen.
Baseline clinical and safety parameters are established prior to drug exposure.
Monitoring for ethambutol-induced optic neuropathy and medication-induced hepatotoxicity requires baseline comparative values.
2
Transition to a two-drug continuation phase with isoniazid and rifampin upon completing 8 weeks of intensive therapy.
The patient successfully completes the intensive phase and appropriately de-escalates to standard continuation therapy.
The intensive phase is fixed at 8 weeks; de-escalation occurs immediately at this mark when susceptibility is known, without delaying for culture results.
3
Review the finalized 8-week follow-up sputum culture, which demonstrates persistent growth of Mycobacterium tuberculosis.
Delayed microbiologic clearance is officially identified.
Cultures drawn at the 8-week mark take several weeks to finalize and are inherently reviewed during the initial portion of the continuation phase.
4
Extend the planned two-drug continuation phase from 4 months to 7 months due to delayed microbiologic clearance.
The total treatment duration is adjusted from 6 months to 9 months.
Patients with cavitary lung disease and a positive 2-month culture have a substantially higher risk of relapse and require a 7-month continuation phase.
5
Assess for treatment completion and verify clinical resolution at the conclusion of the 9-month total therapy course.
Antituberculous therapy is officially concluded.
Final evaluation ensures all extended doses were successfully taken and the patient is clinically cured prior to discharge from the clinic.

Key Concept

The standard monitoring protocol for cavitary pulmonary tuberculosis involves an 8-week intensive phase, transition to a continuation phase, and subsequent retrospective evaluation of 2-month culture results to determine if the treatment duration must be extended from 6 to 9 months.
Estimated Time:1m 30s
Question 3182Question →

A 42-year-old woman is undergoing an elective laparoscopic cholecystectomy for recurrent biliary colic. During the dissection of Calot's triangle, a sudden, brisk, pulsatile hemorrhage occurs, rapidly pooling and obscuring the operative field. The operating surgeon is unable to adequately visualize or isolate the source of the bleeding using the laparoscope despite aggressive suctioning.

Which of the following procedural interventions are indicated immediately? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Conversion to an open laparotomy; Application of direct pressure to the bleeding area with a laparoscopic sponge

Answer

The correct immediate interventions are the application of direct pressure to the bleeding area with a laparoscopic sponge and prompt conversion to an open laparotomy.
In the event of massive, uncontrolled bleeding during a laparoscopic procedure where the source cannot be clearly visualized, the immediate priority is to achieve temporary hemostasis and secure adequate surgical exposure. Applying direct pressure with a laparoscopic sponge provides essential temporary control of the hemorrhage. Concurrently, the procedure must be converted to an open laparotomy to allow for direct visualization, proximal and distal control of the vessels, and safe definitive repair. These steps prevent exsanguination and minimize the risk of iatrogenic injury to surrounding critical structures in Calot's triangle.

Step-by-Step Solution

1
Recognize a life-threatening intraoperative hemorrhage that cannot be controlled or visualized via laparoscopy.
Determination that the current minimally invasive approach is no longer safe.
Continuing laparoscopically without visualization risks catastrophic exsanguination or iatrogenic injury.
2
Apply immediate temporary hemostasis using direct pressure with a laparoscopic sponge.
The rate of hemorrhage is temporarily slowed.
Temporizing the bleed allows the anesthesiologist to stabilize the patient's hemodynamics while the surgical team prepares for the next step.
3
Convert the procedure to an open laparotomy (typically via a right subcostal incision).
The surgeon gains direct manual access and wide visualization of the right upper quadrant.
Direct visualization is strictly required to identify the specific bleeding vessel (e.g., cystic artery avulsion or right hepatic artery injury) and safely achieve definitive ligation.

Key Concept

Management of uncontrolled hemorrhage during laparoscopic surgery
Question 3183Question →

Paramedics arrive at the resuscitation bay with a 61-year-old male who developed crushing, substernal chest pressure radiating to his jaw two hours ago while gardening. He reports severe lightheadedness and nausea. Past medical history is significant for hyperlipidemia and osteoarthritis.

Upon arrival, his temperature is 37.0°C (98.6°F), blood pressure is 74/48 mmHg, heart rate is 52/min, and respiratory rate is 16/min. Oxygen saturation is 96% on room air.

Physical examination reveals a pale, diaphoretic patient. The jugular veins are markedly distended while the patient is sitting at a 45-degree angle. Auscultation of the chest reveals clear breath sounds bilaterally without wheezes or crackles. Heart sounds are distant, and no murmurs are appreciated.

A 12-lead electrocardiogram obtained by triage staff demonstrates 3-mm ST-segment elevations in leads II, III, and aVF, along with reciprocal ST-segment depressions in leads I and aVL.

Which of the following is the most appropriate next step in the initial stabilization of this patient?

Show answer & explanation

Answer: Administration of an isotonic intravenous fluid bolus

Answer

Administration of an isotonic intravenous fluid bolus
The patient is experiencing profound hypotension due to an acute right ventricular (RV) myocardial infarction. This diagnosis is supported by the classic triad of hypotension, elevated jugular venous pressure (JVD), and clear lung fields, occurring alongside an inferior STEMI (ST elevations in II, III, aVF). The ischemic right ventricle becomes stiff and loses its contractile function, making it highly dependent on elevated preload to maintain blood flow to the left ventricle. Therefore, the most critical initial stabilization step is volume expansion with an isotonic intravenous fluid bolus (e.g., normal saline) to increase RV filling pressures and subsequently improve systemic cardiac output.

Step-by-Step Solution

1
Analyze the clinical presentation and vital signs.
The patient has severe hypotension, bradycardia, clear lung fields, and jugular venous distention in the context of an acute ischemic event.
Identifying the specific hemodynamic state is required before intervening.
2
Interpret the electrocardiogram findings.
ST elevations in leads II, III, and aVF indicate an acute inferior myocardial infarction.
Inferior myocardial infarctions frequently involve the right ventricle, altering the standard acute coronary syndrome management pathway.
3
Synthesize findings to determine the underlying pathophysiology.
The triad of hypotension, clear lungs, and jugular venous distention in the setting of an inferior myocardial infarction is highly specific for a right ventricular infarction.
Right ventricular ischemia leads to a stiff right ventricle that relies on high preload to push blood into the pulmonary circulation and subsequently to the left ventricle.
4
Select the most appropriate initial stabilization step.
Administer isotonic intravenous fluids to maximize preload and optimize cardiac output.
Fluid resuscitation directly addresses the preload-dependent state causing the patient's profound hypotension.

Key Concept

Right ventricular myocardial infarction presents with hypotension, elevated jugular venous pressure, and clear lungs, and requires immediate stabilization with isotonic intravenous fluids to maintain adequate preload.
Question 3184Question →

A 61-year-old man visits his primary care provider to establish care and review his preventive health needs. His past medical history is significant for essential hypertension and hyperlipidemia. He currently smokes one pack of cigarettes daily and has done so for the past 30 years (30 pack-year history). His current medications include amlodipine and atorvastatin. A review of his medical records shows that he had a normal screening colonoscopy 6 years ago. He completed the recombinant zoster vaccine series at age 55 and received the current seasonal influenza vaccine at a local pharmacy last month. He denies any chest pain, shortness of breath, cough, or changes in bowel habits. Which of the following preventive interventions are indicated for this patient at this visit? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Low-dose computed tomography of the chest; 20-valent pneumococcal conjugate vaccine

Answer

The indicated interventions are low-dose computed tomography of the chest and the 20-valent pneumococcal conjugate vaccine.
The correct interventions are low-dose computed tomography (LDCT) of the chest and the 20-valent pneumococcal conjugate vaccine. The patient meets the USPSTF criteria for annual LDCT screening because he is between the ages of 50 and 80, has a smoking history of at least 20 pack-years, and is a current smoker. Additionally, current cigarette smoking is an indication for pneumococcal vaccination in adults aged 19 to 64 years, as it significantly increases the risk of invasive pneumococcal disease.

Step-by-Step Solution

1
Evaluate the patient's age and smoking history to determine lung cancer screening eligibility.
The patient is 61 years old with a 30 pack-year smoking history and currently smokes. He meets criteria for annual low-dose computed tomography (LDCT).
Guidelines recommend LDCT for adults aged 50 to 80 years with at least a 20 pack-year smoking history who currently smoke or quit within the last 15 years.
2
Assess the patient's vaccination history and risk factors.
The patient has a history of smoking, which is a qualifying condition for pneumococcal vaccination in adults under 65.
Cigarette smoking compromises respiratory defenses, placing the patient at higher risk for invasive pneumococcal disease.
3
Review the patient's prior screening for colorectal cancer.
The patient had a normal colonoscopy 6 years ago. The next screening is not due for another 4 years.
A normal colonoscopy provides a 10-year screening interval, during which interim testing with other modalities is not recommended.
4
Consider other age-based screening guidelines for this male patient.
Abdominal aortic aneurysm screening and osteoporosis screening are not indicated.
AAA screening begins at age 65 for men who have ever smoked. Routine DEXA scans are generally reserved for women aged 65 and older or those at elevated risk.

Key Concept

Age and risk-factor specific preventive screening guidelines
Question 3185Question →

A 38-year-old woman presents to the urgent care clinic with a 3-day history of extreme fatigue, sore throat, and new-onset bleeding from her gums while brushing her teeth. She has a history of severe Crohn disease that has been well-controlled on daily azathioprine for the past three years. Three weeks ago, she developed a painful, swollen right great toe and was diagnosed with a gout flare. Her primary care physician started her on allopurinol to prevent future attacks. Her temperature is 38.4°C (101.1°F), blood pressure is 112/72 mm Hg, and pulse is 108/min. Physical examination reveals mucosal pallor, oral petechiae, and pharyngeal erythema without exudate. Which of the following is the most appropriate next step in the evaluation and management of this patient?

Show answer & explanation

Answer: Withhold azathioprine and allopurinol, and immediately obtain a complete blood count.

Answer

Withhold azathioprine and allopurinol, and immediately obtain a complete blood count.
The correct answer addresses the critical and potentially fatal drug-drug interaction between azathioprine and allopurinol. Azathioprine is a prodrug that is converted to 6-mercaptopurine (6-MP). 6-MP is subsequently metabolized and inactivated by the enzyme xanthine oxidase. Allopurinol, prescribed for the patient's gout, is a potent xanthine oxidase inhibitor. Coadministration of these two drugs causes a profound decrease in the metabolism of 6-MP, leading to its toxic accumulation. This results in severe bone marrow suppression. The patient's presentation of fever, sore throat, severe fatigue, pallor, and petechiae is the classic triad of pancytopenia: neutropenia, anemia, and thrombocytopenia, respectively. The most appropriate initial step is to immediately withhold both medications and obtain a complete blood count to evaluate the severity of the bone marrow failure.

Step-by-Step Solution

1
Identify the critical drug interaction in the patient's medication history.
The patient is taking both azathioprine and allopurinol.
Azathioprine is converted to 6-mercaptopurine, which is metabolized by xanthine oxidase. Allopurinol inhibits xanthine oxidase, leading to a toxic accumulation of 6-mercaptopurine.
2
Correlate the drug interaction with the patient's physical symptoms.
Fever, sore throat, mucosal pallor, and petechiae are identified as signs of pancytopenia.
The toxic accumulation of 6-mercaptopurine causes severe dose-dependent bone marrow suppression, manifesting as neutropenia (infection/fever), anemia (pallor/fatigue), and thrombocytopenia (petechiae/bleeding).
3
Determine the safest and most appropriate immediate clinical intervention.
The offending medications must be stopped and blood counts must be checked.
Immediate cessation prevents further toxicity, and a complete blood count is the definitive initial diagnostic test to quantify the severity of the myelosuppression.

Key Concept

Patients taking azathioprine or 6-mercaptopurine who are subsequently prescribed allopurinol are at high risk for life-threatening bone marrow suppression due to xanthine oxidase inhibition.
Question 3186Question →

A 52-year-old male who underwent a deceased-donor renal transplantation 8 months ago is evaluated in the inpatient medical ward for a 4-day history of fever, dry cough, and right-sided pleuritic chest pain. His current medications include tacrolimus, mycophenolate mofetil, and prednisone. Temperature is 38.6°C (101.5°F), blood pressure is 132/82 mmHg, pulse is 108/min, and respirations are 20/min. Oxygen saturation is 93% on room air. Laboratory studies reveal a serum creatinine of 1.4 mg/dL (baseline 1.3 mg/dL). A non-contrast CT scan of the chest demonstrates a nodular consolidation with a surrounding ground-glass opacity (halo sign) in the right upper lobe. Bronchoscopy with bronchoalveolar lavage is performed, and galactomannan antigen testing is markedly positive. The infectious disease service recommends initiating intravenous voriconazole. Which of the following is the most appropriate pharmacologic intervention regarding this patient's current medication regimen?

Show answer & explanation

Answer: Decrease the tacrolimus dose and monitor serum trough levels

Answer

Decrease the tacrolimus dose and monitor serum trough levels
The correct intervention is to decrease the tacrolimus dose and closely monitor serum trough levels. Voriconazole, the first-line pharmacotherapy for invasive pulmonary aspergillosis, is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor that relies heavily on CYP3A4 for its metabolism and clearance. Coadministration of these two agents without adjusting the baseline immunosuppressive regimen will rapidly lead to supratherapeutic tacrolimus levels. This significantly increases the risk of severe side effects, most notably acute nephrotoxicity, neurotoxicity (such as tremors or seizures), and over-immunosuppression. Standard clinical guidelines mandate reducing the tacrolimus dose—often by approximately one-third to one-half—when initiating voriconazole, followed by meticulous therapeutic drug monitoring.

Step-by-Step Solution

1
Identify the primary diagnosis and confirm the necessity of the recommended treatment.
The patient's clinical presentation, halo sign on CT, and markedly positive galactomannan antigen confirm invasive pulmonary aspergillosis, which necessitates treatment with voriconazole.
Establishing the correct therapeutic agent is required to evaluate potential drug-drug interactions with the patient's baseline regimen.
2
Analyze the pharmacokinetic properties of both the baseline immunosuppressants and the newly prescribed antifungal.
Voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor heavily metabolized by CYP3A4.
Recognizing this specific enzyme interaction is critical to preventing iatrogenic toxicity.
3
Determine the appropriate dose adjustment strategy to mitigate the interaction.
The tacrolimus dose must be empirically reduced (typically by one-third to one-half) upon starting voriconazole, accompanied by close therapeutic drug monitoring.
Proactive dose reduction prevents supratherapeutic tacrolimus concentrations, which would otherwise lead to severe nephrotoxicity and neurotoxicity.

Key Concept

Initiation of voriconazole, a potent CYP3A4 inhibitor, in a patient taking tacrolimus requires a pre-emptive reduction in the tacrolimus dose and close therapeutic drug monitoring to prevent severe calcineurin inhibitor toxicity.
Question 3187Question →

A physician is evaluating a 67-year-old male patient who reports a nagging, dry cough persisting for three months. The patient, who has a 45-pack-year history of cigarette smoking, denies hemoptysis, night sweats, or unintentional weight loss. His past medical history includes essential hypertension and mild chronic obstructive pulmonary disease. Auscultation of the lungs reveals globally decreased breath sounds without focal adventitious sounds. An initial posteroanterior and lateral chest radiograph is obtained, revealing an incidental 2.2-cm, irregularly shaped, noncalcified density in the apical region of the right lung.

Arrange the following diagnostic interventions in the correct sequential order to properly work up this patient's pulmonary finding, beginning with the immediate next best step.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct diagnostic sequence is to first review prior imaging, followed by a high-resolution CT of the chest, then a PET scan, and finally a tissue biopsy.
The correct sequence prioritizes minimizing patient risk and resource utilization while sequentially gathering diagnostic data. Reviewing prior imaging can immediately halt a costly workup if the lesion is stable. High-resolution CT provides the necessary anatomic detail to determine if a PET scan is warranted. A PET scan then provides metabolic data and staging information, which ultimately guides the safest and most accurate approach for the final, most invasive step: tissue biopsy.

Step-by-Step Solution

1
Determine the need for further imaging by establishing nodule stability over time.
Review of prior imaging is identified as the first step.
A nodule that has been stable in size for more than two years is almost always benign and requires no further invasive or radiating workup.
2
Characterize the nodule's detailed anatomy if prior imaging is unavailable or shows growth.
High-resolution CT is selected as the second step.
CT delineates morphology, calcification patterns, and regional anatomy with much higher fidelity than plain radiographs.
3
Assess the metabolic activity of the lesion and screen for occult metastases.
FDG-PET scan is selected as the third step.
PET guides staging and identifies the best target for biopsy in high-risk, solid nodules larger than 8 mm.
4
Obtain definitive histopathologic confirmation of the lesion.
Image-guided biopsy is the final step.
Invasive testing should only follow complete non-invasive staging, which dictates the safest and highest-yield approach.

Key Concept

The diagnostic sequencing of a newly discovered solitary pulmonary nodule prioritizes historical data first (prior imaging), followed by detailed anatomic characterization (high-resolution CT), metabolic assessment and staging (PET scan), and finally invasive tissue sampling (biopsy).
Estimated Time:1m 30s
Question 3188Question →

A systematic review is aggregating data from various study designs to evaluate a new class of pharmacological agents. Different trials report their primary and secondary outcomes using distinct statistical metrics. Match each specific trial finding or calculation methodology to the most appropriate measure of association or impact.

Click a left item, then click its matching right item

Items

The study notes a 15%15\% incidence of adverse gastrointestinal events in the treatment arm compared to 5%5\% in the placebo arm, reporting a raw difference of 10%10\%.
Researchers determine that taking the reciprocal of the risk difference between treatment and control groups yields a value of 2525, indicating the patient volume required to receive the intervention to prevent one myocardial infarction.
A retrospective case-control study reports a cross-product ratio of 3.23.2 when comparing prior drug exposure in patients with acute hepatotoxicity versus those without the condition.
A 10-year prospective cohort study indicates that the cumulative incidence of heart failure in the exposed group divided by the cumulative incidence in the unexposed group equals 1.41.4.

Matches

Show answer & explanation

Answer

The correct matches link the raw difference in adverse event incidence to Absolute Risk Increase, the inverse of risk difference to Number Needed to Treat, the cross-product ratio in a case-control study to Odds Ratio, and the incidence rate ratio in a cohort study to Relative Risk.
Each specific clinical scenario strictly dictates a distinct epidemiological measure based on study architecture: subtraction of risks yields absolute differences (ARI/ARR), reciprocals of absolute differences yield NNT/NNH, prospective ratios yield Relative Risk, and retrospective cross-products yield Odds Ratios.

Step-by-Step Solution

1
Identify the metric describing the direct subtraction of adverse event rates.
Matches with Absolute Risk Increase (ARI).
ARI is calculated as the incidence of a harmful outcome in the exposed minus the incidence in the unexposed.
2
Identify the metric representing the reciprocal of the risk difference.
Matches with Number Needed to Treat (NNT).
NNT=1/ARRNNT = 1 / ARR, which quantifies the clinical impact of a beneficial intervention by showing how many patients must be treated to prevent one adverse event.
3
Identify the metric derived from cross-product ratios in a retrospective design.
Matches with Odds Ratio (OR).
Case-control studies cannot directly measure incidence, so they rely on the ratio of odds of exposure, calculated as (a×d)/(b×c)(a \times d) / (b \times c).
4
Identify the metric representing the ratio of incidence rates in a prospective design.
Matches with Relative Risk (RR).
Cohort studies follow patients forward in time, allowing direct calculation of incidence. The ratio of the exposed incidence to the unexposed incidence is the RR.

Key Concept

Selecting the appropriate biostatistical measure of association or impact requires understanding the underlying study design and the specific mathematical derivation of the metric.
Question 3189Question →

A 48-year-old woman comes to the clinic for a routine health maintenance visit. She was diagnosed with chronic hepatitis C virus (HCV) infection 6 years ago. At the time of diagnosis, transient elastography demonstrated a liver stiffness of 16 kPa16 \text{ kPa}, consistent with compensated cirrhosis. She was subsequently treated with a 12-week course of direct-acting antivirals and achieved a sustained virologic response (cure) 5 years ago. She has no history of ascites, hepatic encephalopathy, or variceal bleeding.

She feels well and has no current symptoms. She takes no medications and does not use alcohol, tobacco, or illicit drugs.

Vital signs are within normal limits. Physical examination reveals a palpable, firm liver edge but no splenomegaly, jaundice, or stigmata of chronic liver disease.

Recent laboratory studies show:
Laboratory TestResultReference Range
Platelet count175,000/mm3175,000/\text{mm}^3150,000−400,000/mm3150,000-400,000/\text{mm}^3
Total bilirubin0.9 mg/dL0.9 \text{ mg/dL}0.1−1.2 mg/dL0.1-1.2 \text{ mg/dL}
Alanine aminotransferase (ALT)22 U/L22 \text{ U/L}10−40 U/L10-40 \text{ U/L}
Aspartate aminotransferase (AST)24 U/L24 \text{ U/L}10−40 U/L10-40 \text{ U/L}
International normalized ratio (INR)1.11.10.8−1.10.8-1.1

Her most recent screening mammogram 6 months ago was normal. Her last colonoscopy at age 45 was normal.

Vaccination history includes a complete hepatitis A and B series, the 20-valent pneumococcal conjugate vaccine (PCV20) 2 years ago, Tdap 3 years ago, and the annual influenza vaccine.

Which of the following is the most appropriate next step in this patient's preventive management?

Show answer & explanation

Answer: Abdominal ultrasonography

Answer

Abdominal ultrasonography
The correct answer is abdominal ultrasonography. Patients with chronic hepatitis C virus (HCV) infection who develop cirrhosis remain at a significantly elevated risk for hepatocellular carcinoma (HCC), even after achieving a sustained virologic response (SVR, or virologic cure) with direct-acting antivirals. Therefore, current guidelines from the American Association for the Study of Liver Diseases (AASLD) recommend lifelong HCC surveillance for all patients with cirrhosis, regardless of the etiology or viral cure status. The standard surveillance modality is abdominal ultrasonography every 6 months, with or without serum alpha-fetoprotein (AFP) testing.

Step-by-Step Solution

1
Identify the patient's underlying chronic conditions and treatment history.
The patient has a history of chronic HCV that was successfully treated (SVR), but she developed compensated cirrhosis prior to treatment.
Preventive care guidelines in hepatology are heavily influenced by the presence of irreversible architectural liver damage (cirrhosis), regardless of the current viral status.
2
Determine the ongoing screening requirements for a patient with cirrhosis post-HCV cure.
Because liver fibrosis and cirrhosis persist despite viral cure, the risk of hepatocellular carcinoma (HCC) remains significantly elevated.
AASLD guidelines mandate lifelong HCC screening (using abdominal ultrasonography every 6 months) for any patient who has developed cirrhosis.
3
Evaluate the need for other cirrhosis-related screenings, such as for esophageal varices.
The patient has a platelet count > 150,000/mm³ and a liver stiffness < 20 kPa.
According to the Baveno criteria, patients meeting these specific thresholds are at a very low risk for clinically significant varices and can safely defer screening esophagogastroduodenoscopy (EGD).
4
Review age-based preventive care and vaccine history.
The patient is up to date on colon cancer screening, breast cancer screening, and all indicated vaccines.
Confirms that no other routine primary care interventions take precedence over HCC screening.

Key Concept

Patients with cirrhosis caused by hepatitis C virus who achieve a sustained virologic response (cure) remain at high risk for hepatocellular carcinoma and require lifelong surveillance with abdominal ultrasonography every 6 months.
Question 3190Question →

A public health researcher is designing a study to investigate whether short-term use of high-dose oral corticosteroids is associated with an increased risk of acute psychiatric admissions. The outcome of interest is acute, and the suspected trigger is a transient exposure. To comprehensively account for unmeasured time-invariant confounding variables such as genetic predisposition, baseline psychiatric history, and stable socioeconomic factors, the investigator designs a protocol that identifies patients recently admitted for acute psychosis. The frequency of corticosteroid prescriptions in the 30-day period immediately preceding each patient's admission is then compared to the frequency of corticosteroid prescriptions in a 30-day control period exactly one year prior for those exact same individuals. Which of the following best describes this study design?

Show answer & explanation

Answer: Case-crossover study

Answer

Case-crossover study
The correct answer accurately identifies a study design tailored for transient exposures (short-term corticosteroid use) and acute outcomes (psychiatric admission). By comparing the exposure status during a 'hazard period' just before the event to a 'control period' at a previous time in the exact same individual, the investigator eliminates the influence of time-invariant confounders (e.g., genetics, chronic conditions). This is the hallmark of a case-crossover study.

Step-by-Step Solution

1
Analyze the starting point and directionality of the investigation.
The researcher identifies patients who already have the outcome (acute psychiatric admission) and looks backward at their exposure history, making it a retrospective observational analysis.
Determining the directionality distinguishes cohort studies (exposure to outcome) from case-control and similar backward-looking designs.
2
Evaluate the nature of the control group used in the study.
The investigator compares the exposure in the period immediately before the event to an earlier control period within the exact same individuals.
Recognizing that patients serve as their own controls eliminates traditional case-control studies where different individuals are compared.
3
Synthesize the design features to identify the specific epidemiological method.
An observational study assessing a transient exposure for an acute event, where each case serves as their own control at a different time point to eliminate time-invariant confounding, is characteristic of a case-crossover study.
This confirms the correct study design while ruling out experimental crossover trials.

Key Concept

Case-crossover study design characteristics and indications
Question 3191Question →

A 20-year-old male college student comes to the university health clinic for a follow-up visit. He has a history of moderate persistent asthma and was treated in the emergency department two weeks ago for a severe exacerbation. At a clinic visit two months ago, he was prescribed a daily inhaled corticosteroid (budesonide) and an as-needed short-acting beta-agonist (albuterol). Today, the patient reports using his rescue inhaler almost every day but admits he has not used the daily preventative inhaler. When asked about this discrepancy, the patient states, 'I refuse to take a daily steroid. I am training hard to make the regional track and field team, and I absolutely cannot risk getting disqualified for doping or gaining a bunch of unnatural muscle mass.'

Which of the following is the most appropriate response by the physician?

Show answer & explanation

Answer: It is understandable to be protective of your athletic eligibility. The medication in your inhaler reduces lung inflammation and is completely different from the anabolic steroids that build muscle.

Answer

Validate the patient's concern regarding his athletic eligibility and provide targeted education explaining the difference between inhaled corticosteroids and anabolic steroids.
The most appropriate response directly addresses the patient's knowledge deficit while validating his underlying concern. The patient's nonadherence is rooted in confusing inhaled corticosteroids (which treat airway inflammation and are universally permitted in athletic competition) with anabolic-androgenic steroids (which promote muscle hypertrophy and are banned). By acknowledging the importance of his athletic goals and then providing clear, factual education, the physician fosters a strong therapeutic alliance and encourages medication adherence.

Step-by-Step Solution

1
Identify the patient's core concern and reason for nonadherence.
The patient is refusing his daily controller medication because he fears disqualification from sports and unnatural muscle hypertrophy.
Understanding the specific barrier to adherence is required before intervening.
2
Analyze the nature of the concern.
The concern is based on a fundamental misunderstanding of pharmacology, specifically confusing inhaled corticosteroids with anabolic-androgenic steroids.
Distinguishing between a valid side-effect concern and a knowledge deficit dictates the counseling approach.
3
Select the appropriate counseling strategy.
Empathize with the patient's dedication to his sport, then provide clear, factual education to correct the misconception.
Directly addressing the misconception in a supportive, non-judgmental manner is the most effective way to improve adherence.

Key Concept

Addressing medication nonadherence by exploring patient beliefs and correcting pharmacological misconceptions in a non-judgmental manner.
Question 3192Question →

Match each clinical presentation in the palliative care setting with the most appropriate next step in management.

Click a left item, then click its matching right item

Items

A 72-year-old woman with end-stage chronic obstructive pulmonary disease who experiences severe, unrelenting breathlessness at rest despite maximal inhaler therapy.
A 55-year-old man with metastatic pancreatic cancer who develops generalized myoclonus, hallucinations, and hyperalgesia after a recent dose increase of oral morphine.
A 64-year-old woman with metastatic breast cancer to the spine who reports severe, localized, aching pain in her mid-back that worsens with movement.
A 79-year-old man with terminal lung cancer and multi-organ failure who exhibits severe, intractable agitation and distress in his final hours despite administration of haloperidol and opioids.

Matches

Show answer & explanation

Answer

The COPD patient requires low-dose oral opioids; the patient with opioid-induced neurotoxicity requires opioid rotation and intravenous hydration; the patient with localized metastatic bone pain requires referral for palliative external beam radiation therapy; and the patient with terminal delirium requires initiation of palliative sedation with an intravenous benzodiazepine.
Each clinical scenario requires a specific, distinct palliative intervention. Refractory dyspnea in advanced COPD is treated with low-dose systemic opioids to reduce the central respiratory drive and the sensation of breathlessness. Opioid-induced neurotoxicity, presenting as myoclonus and hyperalgesia, is managed by clearing active metabolites with hydration and rotating to a different opioid to avoid cross-tolerance. Severe, localized pain from metastatic bone disease is highly responsive to palliative external beam radiation therapy. Lastly, when a patient in the final hours of life experiences intractable agitation that does not respond to standard treatments, palliative sedation (often with a benzodiazepine like midazolam) is ethically and clinically indicated to relieve suffering.

Step-by-Step Solution

1
Identify the primary distressing symptom and underlying clinical context for each patient.
Patient 1 has refractory dyspnea; Patient 2 has opioid-induced neurotoxicity; Patient 3 has localized metastatic bone pain; Patient 4 has refractory terminal delirium.
Accurate characterization of distinct palliative symptom syndromes dictates the choice of targeted therapy.
2
Determine the evidence-based standard of care for each identified symptom presentation.
Dyspnea is managed with opioids. Opioid neurotoxicity requires rotation and hydration. Localized bone pain responds to radiation. Refractory terminal agitation requires palliative sedation.
Applying standard palliative care protocols ensures effective symptom control and avoids common pharmacological errors.

Key Concept

Targeted symptom management in end-of-life care
Question 3193Question →

A clinical research team is investigating a potential link between a newly approved monoclonal antibody therapy and the development of progressive multifocal leukoencephalopathy (PML), an extremely rare demyelinating disease. They query a multi-state hospital network's electronic health records to identify 30 patients diagnosed with PML over the past five years. For comparison, they randomly select 120 patients from the same network who have similar underlying autoimmune conditions but have never been diagnosed with PML. The researchers then review the historical pharmacy records of all 150 patients to ascertain their prior exposure to the monoclonal antibody. Which of the following statements regarding this study design are correct?

Select all that apply

Show answer & explanation

Answer: The investigators can calculate an odds ratio to estimate the magnitude of the association between the therapy and the disease.; The chosen methodology is particularly well-suited for this investigation because the neurological outcome of interest has a very low prevalence.

Answer

The correct statements are that the investigators can calculate an odds ratio to estimate the magnitude of the association, and that the chosen methodology is particularly well-suited for this investigation because the neurological outcome of interest has a very low prevalence.
The scenario describes a case-control study, as patients were grouped by their disease outcome (PML vs. no PML) before their past exposure to the monoclonal antibody was analyzed. Case-control studies are the optimal observational design for investigating rare diseases because they ensure an adequate sample of diseased subjects without requiring a massive, prolonged cohort study. Additionally, because the ratio of cases to controls is artificially selected by the researchers, it is mathematically impossible to calculate true incidence or relative risk; instead, the odds ratio is calculated to approximate the strength of the association.

Step-by-Step Solution

1
Identify the study design described in the clinical vignette.
The researchers identified subjects based on the presence of the disease (cases with PML) or the absence of the disease (controls without PML) and then looked back at historical records for exposure.
Grouping patients by outcome status rather than exposure status is the defining characteristic of a case-control study.
2
Determine the appropriate statistical measures and limitations for the identified design.
Case-control studies use the odds ratio to estimate association. They cannot measure incidence or true relative risk directly.
The investigator artificially sets the number of cases and controls, breaking the natural incidence rate found in the general population.
3
Evaluate the epidemiological indications for this specific study design.
The design is highly optimal for rare diseases like progressive multifocal leukoencephalopathy.
Following a healthy cohort forward to find enough cases of an extremely rare disease would be prohibitively expensive and time-consuming.
4
Analyze the effect of the control selection criteria.
Selecting controls with similar underlying conditions controls for confounding but prevents analyzing that specific condition as a risk factor.
If a variable is uniform or intentionally matched between the case and control groups, its independent effect on the outcome cannot be statistically evaluated.

Key Concept

Case-control studies identify subjects by disease status, utilize odds ratios to estimate association, are highly efficient for investigating rare diseases, and preclude the analysis of matched variables as independent risk factors.
Question 3194Question →

A 52-year-old woman with a 30-pack-year smoking history and poorly controlled hypertension presents to the clinic for a follow-up visit. During the encounter, the physician utilizes principles of Motivational Interviewing and patient-centered communication to discuss lifestyle modifications. Match each physician communication technique to the specific statement that best demonstrates its clinical application.

Click a left item, then click its matching right item

Items

Affirmation
Normalizing
Reflective listening
Evoking change talk

Matches

Show answer & explanation

Answer

The correct matches are: Affirmation to praising her blood pressure checks; Normalizing to explaining her overwhelmed feelings are common; Reflective listening to mirroring her frustration with cravings; and Evoking change talk to asking for her reasons for quitting.
The correct matching perfectly aligns core patient-centered communication strategies with their practical clinical applications. Affirmation builds patient confidence by highlighting specific successes. Normalizing reduces feelings of isolation by validating common emotional responses. Reflective listening proves the physician is accurately hearing and understanding the patient's core struggles without judgment. Finally, Evoking change talk shifts the clinical focus away from physician-led advice and toward the patient's own internal motivations.

Step-by-Step Solution

1
Analyze the 'Affirmation' technique and identify the statement that highlights the patient's positive actions or strengths.
Matched with the statement praising the patient for checking her blood pressure daily.
Affirmations must focus on genuine, specific positive behaviors rather than general praise.
2
Evaluate the remaining statements for 'Normalizing'.
Matched with the statement explaining that it is extremely common and understandable to feel overwhelmed.
Normalizing requires comparing the patient's reaction to a universal or typical human experience to validate their feelings.
3
Identify 'Reflective listening' by finding the statement where the physician mirrors the patient's expressed emotions and struggles.
Matched with the statement reflecting the patient's frustration regarding cigarette cravings.
Reflections are declarative statements (not questions) that capture the essence of the patient's experience.
4
Match 'Evoking change talk' to the remaining statement that utilizes an open-ended inquiry.
Matched with the question asking for the patient's most important reasons to consider quitting smoking.
Evoking aims to draw out the patient's own arguments for change, which is a core tenet of Motivational Interviewing.

Key Concept

Application of core Motivational Interviewing (MI) and patient-centered communication techniques in clinical counseling.
Question 3195Question →

During a scheduled annual health review, a 46-year-old female patient voices deep concerns about her familial cancer risk. She notes that her mother received a diagnosis of epithelial ovarian cancer one month ago at the age of 68. Furthermore, her maternal aunt was treated for breast cancer diagnosed at age 52. Her medical background includes uncomplicated essential hypertension managed with lisinopril. Preventive care records demonstrate a negative screening colonoscopy performed 14 months ago, a negative digital mammogram completed 3 months ago, and a normal cervical cytology with negative high-risk human papillomavirus (HPV) co-testing conducted 2 years prior. Today's physical assessment, including a comprehensive clinical breast examination, reveals no abnormalities. Vital signs are within normal limits. Based on current evidence-based guidelines, which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Provide a referral for familial cancer susceptibility genetic counseling

Answer

Provide a referral for familial cancer susceptibility genetic counseling
The correct action is to provide a referral for genetic counseling. According to the United States Preventive Services Task Force (USPSTF), primary care providers should evaluate women with a family history of breast, ovarian, tubal, or peritoneal cancer to identify those at risk for potentially harmful BRCA1 or BRCA2 mutations. Because this patient has a first-degree relative with ovarian cancer, she is considered high-risk. The evidence-based next step is formal genetic counseling, which must occur before genetic testing or transitioning to high-risk screening modalities.

Step-by-Step Solution

1
Analyze the patient's family history for high-risk cancer patterns.
The patient has a first-degree relative (mother) with ovarian cancer and a second-degree relative (aunt) with breast cancer.
Identifying specific familial patterns is necessary to determine if standard risk-based screening guidelines apply or if the patient requires high-risk management.
2
Evaluate the current USPSTF guidelines regarding BRCA-related cancer screening.
A first-degree relative with ovarian cancer at any age meets the criteria for a positive familial risk assessment.
Guidelines mandate that primary care providers identify women with a family history of breast, ovarian, tubal, or peritoneal cancer.
3
Determine the appropriate sequential intervention for a positive familial risk assessment.
The indicated intervention is a referral for formal genetic counseling, rather than immediately ordering advanced imaging or tumor markers.
Genetic counseling ensures the patient understands the implications of genetic testing before proceeding to specialized surveillance (like MRI) or prophylactic measures.

Key Concept

Women with a strong family history of BRCA-associated cancers (such as a first-degree relative with ovarian cancer at any age) should be referred for genetic counseling before any alterations are made to their imaging or laboratory screening protocols.
Estimated Time:1m 30s
Question 3196Question →

A 42-year-old man presents to the clinic for a health maintenance examination. He recently applied for a life insurance policy and was required to undergo a comprehensive metabolic panel. The patient brings the laboratory report, which shows a total bilirubin level of 1.7 mg/dL with a direct bilirubin of 0.2 mg/dL. The remainder of the panel, including aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase, is within normal limits. A complete blood count and reticulocyte count are normal. The patient appears visibly agitated, pacing the examination room. He states, "My uncle died a painful death from liver cancer last year. I read online that high bilirubin means the liver is failing. Do I need chemotherapy or a transplant?" Which of the following is the most appropriate initial response by the physician?

Show answer & explanation

Answer: It is terrifying to see an abnormal test result after losing your uncle to liver disease. Let's discuss what these specific numbers mean for your health.

Answer

The most appropriate initial response is to validate the patient's intense fear regarding his uncle's death before transitioning into a discussion about what the specific laboratory results mean.
The correct answer prioritizes empathetic validation of the patient's distress before providing clinical education. The patient is experiencing severe anxiety driven by his uncle's death and internet misinformation. In health education and counseling, providing medical facts (such as diagnosing Gilbert syndrome) before addressing intense emotional concerns is often ineffective, as the patient's cognitive bandwidth is consumed by fear. Acknowledging the fear explicitly builds the therapeutic alliance and prepares the patient to accurately receive and understand the subsequent reassurance that his liver is functioning normally.

Step-by-Step Solution

1
Interpret the laboratory findings in the clinical context.
The patient has isolated indirect hyperbilirubinemia with normal transaminases, alkaline phosphatase, and complete blood count.
This presentation is classically consistent with Gilbert syndrome, a benign, inherited condition that requires no treatment or further diagnostic imaging.
2
Assess the patient's emotional state and immediate needs.
The patient is highly agitated, exhibiting severe anxiety driven by a traumatic family history and internet misinformation.
Recognizing the emotional state is critical because severe anxiety impairs a patient's ability to process and retain medical education.
3
Apply patient-centered communication frameworks (e.g., NURSE protocol).
Select the response that explicitly names and validates the patient's fear before providing the clinical diagnosis.
Establishing a strong therapeutic alliance through empathy lowers emotional barriers, allowing subsequent health education about Gilbert syndrome to be effective and reassuring.

Key Concept

Empathetic communication and emotional validation prior to providing health education
Estimated Time:1m 15s
Question 3197Question →

A 55-year-old man is evaluated in the emergency department for progressive abdominal distension and bilateral lower extremity edema over the past 3 weeks. He has a history of chronic hepatitis C infection and alcohol use disorder. On physical examination, his vital signs are stable. The abdomen is distended with prominent shifting dullness and a positive fluid wave. A diagnostic paracentesis is performed, yielding clear, yellow fluid.

Concurrent laboratory studies show:

Serum:
Albumin: 3.1 g/dL
Total protein: 6.5 g/dL
Total bilirubin: 2.5 mg/dL

Ascitic fluid:
Albumin: 1.3 g/dL
Total protein: 2.2 g/dL
Leukocyte count: 210/mm³ (10% neutrophils, 90% mononuclear cells)

To help determine the etiology of the patient's ascites, the physician calculates the serum-ascites albumin gradient (SAAG). What is the patient's SAAG in g/dL?

Show answer & explanation

Answer: 1.8

Answer

1.8
The patient's SAAG is 1.8 g/dL. SAAG is correctly calculated by subtracting the ascitic fluid albumin concentration (1.3 g/dL) from the serum albumin concentration (3.1 g/dL). A SAAG of 1.1 g/dL or greater indicates that the ascites is driven by portal hypertension (such as from hepatic cirrhosis), which aligns with this patient's history of hepatitis C and alcohol use.

Step-by-Step Solution

1
Identify the formula for calculating SAAG.
SAAG = Serum Albumin - Ascitic Fluid Albumin
The SAAG formula is required to classify the ascites as related to portal hypertension or another etiology.
2
Locate the patient's serum albumin and ascitic fluid albumin levels from the laboratory data.
Serum albumin is 3.1 g/dL, and ascitic fluid albumin is 1.3 g/dL.
Accurate identification of the specific albumin values is necessary, avoiding confusion with total protein levels.
3
Subtract the ascitic fluid albumin from the serum albumin.
3.1 - 1.3 = 1.8
Executing the subtraction provides the final SAAG value.

Key Concept

The serum-ascites albumin gradient (SAAG) is calculated by subtracting the ascitic fluid albumin from the serum albumin, with a value ≥ 1.1 g/dL indicating portal hypertension.
Question 3198Question →

A 68-year-old man presents to the ambulatory clinic to establish care. He recently relocated and states he has not seen a healthcare provider or had any medical screenings in over 10 years. His past medical history is significant for hypertension and hyperlipidemia. He has a 40-pack-year smoking history but successfully quit smoking 18 years ago. He currently takes amlodipine and atorvastatin. Vital signs show a blood pressure of 128/78 mmHg, heart rate of 72/min, and a BMI of 27 kg/m 2^2. Physical examination is unremarkable. Which of the following preventive interventions are indicated for this patient at today's visit? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: One-time screening for an abdominal aortic aneurysm with ultrasonography; Administration of the 20-valent pneumococcal conjugate vaccine; Screening for colorectal cancer with a colonoscopy

Answer

The correctly indicated preventive interventions for this patient are one-time screening for an abdominal aortic aneurysm, administration of the 20-valent pneumococcal conjugate vaccine, and screening for colorectal cancer with a colonoscopy.
The patient meets strict criteria for three preventive interventions. First, as a man aged 65 to 75 with a history of smoking, he requires a one-time abdominal aortic aneurysm screening with ultrasonography. Second, as an adult over the age of 65, he requires pneumococcal vaccination (e.g., PCV20). Third, as an adult between the ages of 45 and 75 who has not had medical care in a decade, he requires routine colorectal cancer screening (e.g., via colonoscopy).

Step-by-Step Solution

1
Evaluate patient demographics and basic risk profile.
The patient is a 68-year-old male with a history of hypertension, hyperlipidemia, and a 40-pack-year smoking history (quit 18 years ago). He has had no preventive care in over a decade.
Age, biological sex, and specific risk factors (like smoking history duration and cessation date) dictate USPSTF and ACIP screening guidelines.
2
Assess indicated cancer screenings.
Colorectal cancer screening is indicated because he is between the ages of 45 and 75. Lung cancer screening is contraindicated because his smoking cessation date (18 years ago) exceeds the 15-year cutoff.
Accurately applying age and temporal cutoffs prevents over-screening and adheres to evidence-based recommendations.
3
Assess indicated vascular and metabolic screenings.
Abdominal aortic aneurysm (AAA) screening is indicated because he is a male aged 65-75 with a history of smoking. Osteoporosis screening is not indicated because routine DEXA scans are reserved for women aged 65 and older.
AAA screening is strictly tied to biological sex (male) and any smoking history. Routine DEXA is tied to biological sex (female) unless specific high-risk conditions are present in men.
4
Assess indicated immunizations.
Pneumococcal vaccination (e.g., PCV20) is indicated because he is ≥\ge 65 years old and unvaccinated.
ACIP guidelines universally recommend pneumococcal immunization for adults aged 65 and older.

Key Concept

Application of age-specific, sex-specific, and risk-factor-specific preventive care guidelines (USPSTF and ACIP) in older adults.
Question 3199Question →

An occupational health research group conducts a prospective cohort study to investigate the association between chronic exposure to a newly introduced synthetic resin and the development of interstitial lung disease (ILD). The study enrolls 4,5004,500 manufacturing workers, categorized into high-exposure and low-exposure groups based on their job roles, and follows them for 1515 years. At the conclusion of the observation period, the incidence of ILD is slightly higher in the high-exposure group. The calculated relative risk (RR) is 2.12.1, with a 95%95\% confidence interval (CI) of 0.80.8 to 5.55.5 and a pp-value of 0.120.12. The researchers publish a report concluding that the synthetic resin does not increase the risk of ILD.

Which of the following statistical concepts best explains the primary limitation of the researchers' conclusion?

Show answer & explanation

Answer: Insufficient statistical power due to the low absolute number of observed disease events increases the probability of a Type II error.

Answer

Insufficient statistical power due to the low absolute number of observed disease events increases the probability of a Type II error.
The correct answer identifies that the study is likely underpowered. Statistical power is the probability of correctly rejecting the null hypothesis when a true difference exists (i.e., avoiding a Type II error). In a cohort study, power depends on the alpha level, the magnitude of the effect, and the sample size. Crucially, for rare outcomes like interstitial lung disease (ILD), power is primarily determined by the absolute number of incident events rather than the total number of enrolled subjects. Despite enrolling 4,5004,500 workers, the rarity of ILD likely resulted in very few actual cases. This low event rate leads to high variance, generating a very wide confidence interval (0.80.8 to 5.55.5) and a non-significant pp-value (0.120.12). A common statistical pitfall is concluding that 'absence of evidence is evidence of absence.' The authors' conclusion that the resin does not increase ILD risk is flawed because the wide CI and low power mean a clinically significant risk (e.g., RR of 2.12.1) cannot be ruled out. Thus, the risk of a Type II error (a false negative) is high.

Step-by-Step Solution

1
Analyze the study results and the researchers' conclusion.
The study found an RR of 2.12.1, but the CI crosses 1.01.0 (0.80.8 to 5.55.5) and p>0.05p > 0.05. The researchers definitively concluded there is no risk based on this.
To identify the mismatch between the statistical findings and the authors' definitive conclusion.
2
Evaluate the relationship between outcome frequency, confidence intervals, and power.
ILD is a rare disease. In cohort studies with rare outcomes, power is limited by the absolute number of incident disease events, not just total enrollment. Few events cause wide CIs.
To determine why the study failed to find statistical significance despite a large relative risk point estimate.
3
Correlate the findings with standard statistical errors.
Failing to detect a true difference (a false negative) is a Type II error. The low power due to the rare outcome increases the risk of this error.
To identify the primary statistical limitation of concluding 'no risk' from a non-significant result.

Key Concept

In clinical studies, especially those evaluating rare outcomes, failure to achieve statistical significance (p>0.05p > 0.05) may be due to low statistical power (Type II error) rather than a true absence of association. Statistical power in these scenarios is highly dependent on the absolute number of events.
Question 3200Question →

During difficult clinical encounters, physicians frequently utilize the NURSE framework to respond empathetically to patient emotions. An oncologist is delivering a new diagnosis of advanced malignancy to several different patients, each of whom responds with a strong emotional reaction. Match each patient's emotional statement to the most appropriate physician empathetic response technique.

Click a left item, then click its matching right item

Items

I just cannot believe this is happening. There must be a mix-up with the lab results; I have always been perfectly healthy!
Why didn't my previous doctor catch this earlier? If they had just ordered the scan last year, I wouldn't be in this situation!
I don't think I have the strength to endure chemotherapy. I barely made it through the diagnostic biopsy without collapsing.
What if the targeted therapy doesn't work? My kids are in high school, and the thought of them growing up without a parent is unbearable.

Matches

Show answer & explanation

Answer

Match the patient's shock to Naming, the anger about delayed diagnosis to Understanding, the self-doubt about chemotherapy to Respecting, and the anxiety about children to Exploring.
Effective health behavior counseling and bad news delivery require matching the physician's empathetic response to the patient's specific emotional state. The NURSE framework (Naming, Understanding, Respecting, Supporting, Exploring) provides targeted responses: Naming addresses shock; Understanding de-escalates anger; Respecting combats self-doubt; and Exploring addresses underlying anxiety.

Step-by-Step Solution

1
Analyze the first patient's statement for the core emotional response.
The statement indicates profound shock and disbelief.
Accurate emotional assessment is required to apply the correct NURSE framework component.
2
Select the corresponding empathetic technique for shock.
Naming the emotion.
Explicitly articulating the emotion helps the patient process the sudden news.
3
Evaluate the second statement's core emotion.
The patient is expressing anger and assigning blame regarding the timeline.
Identifying anger prevents the physician from reacting defensively.
4
Select the technique for de-escalating anger and blame.
Understanding / Legitimizing.
Legitimizing the patient's right to feel frustrated builds therapeutic alliance without assigning medical fault.
5
Assess the third statement and select the appropriate response.
The patient feels weak and defeated; the 'Respecting' technique is most appropriate.
Highlighting past coping skills and praising resilience builds self-efficacy.
6
Assess the fourth statement and select the appropriate response.
The patient is deeply anxious about their family; 'Exploring' is most appropriate.
Prompting the patient to elaborate helps uncover the specific root of their anxiety.

Key Concept

NURSE Framework for Empathetic Communication
PreviousPage 160 / 237Next
All practice questions — USMLE Step 3 | Examkin